Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Beyond Air ( (XAIR) ) has shared an update.
On September 8, 2025, Beyond Air announced an agreement with holders of existing warrants to purchase 1,439,126 shares at a reduced price, generating approximately $3.18 million in gross proceeds. In return, the company will issue new unregistered warrants for 719,561 shares. The proceeds will support clinical and pre-clinical programs, with the transaction closing expected on September 9, 2025.
The most recent analyst rating on (XAIR) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.
Spark’s Take on XAIR Stock
According to Spark, TipRanks’ AI Analyst, XAIR is a Neutral.
Beyond Air’s overall stock score reflects a company in transition, with significant revenue growth and strategic developments offset by ongoing financial challenges. The most significant factors are the strong earnings call and positive corporate events, which provide optimism for future growth. However, the current financial performance and valuation remain weak, limiting the overall score.
To see Spark’s full report on XAIR stock, click here.
More about Beyond Air
Beyond Air is a commercial stage medical device and biopharmaceutical company focused on utilizing nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors. The company has FDA approval for its LungFit® PH system for treating hypoxic respiratory failure in neonates and is advancing other LungFit systems for severe lung infections and neurological disorders.
Average Trading Volume: 3,008,419
Technical Sentiment Signal: Sell
Current Market Cap: $11.55M
For detailed information about XAIR stock, go to TipRanks’ Stock Analysis page.